Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer

Lilly previously announced that the trial met its primary endpoint of investigator-assessed progression-free survival (PFS); those results were presented at the European Society for Medical Oncology (ESMO) 2017 Congress and simultaneously published in The ...